MRONJ

Islam Kassem, BDS , MSc, MOMS RCPS Glasg, FFD RCSI
Oral & Maxillofacial Surgeon
Doha, Qatar
21 February 2015
Bisphosphonate Related
Osteonecrosis of the Jaws
ismohammed@phcc.gov.qa
BRONJ

Declaration
 There is no conflict of interest in this Lecture .
 I have no monetary benefit from this Lecture.
 No implied sponsorship by any company to the
speaker
 All patients in the presentation had an informed
consent for photography & publication

Islam Kassem, BDS , MSc, MOMS RCPS Glasg
Oral & Maxillofacial Surgeon
Alexandria university Hospital
Cairo
National institute of cancer
Scientific day of Head & neck surgery unit
12 March 2009
Bisphosphonate & Osteonecrosis
of the mandible, case report
ikassem@dr.com

Objectives
 Bisphosphonates
 Clinical applications
 Drug chemistry
 Biologic action
 BRONJ
 Pathogenesis
 Treatment of BRONJ
 Latest management recommendations
 Updates in the literature
 Case Presentations
 Latest PubMed search produced 1473 articles on Bisphosphonate
Related Osteonecrosis of the Jaw. (BRONJ)

Bisphosphonates – what are
they? Class of drugs
 High affinity for calcium
– Binds to bone surfaces
– Nitrogen: increased affinity, potency
 Prevent bone resorption and remodeling
 IV and oral formulations
– IV: tx for bone resorption 2° metastatic
tumors, osteolytic lesions
– Oral: tx for osteoporosis, osteopenia

Bisphosphonates: Common uses
 Prevention and treatment of osteoporosis in
postmenopausal women
 Increase bone mass in men with osteoporosis
 Tx of glucocorticoid-induced osteoporosis
 Tx of Paget’s disease of bone
 Hypercalcemia of malignancy
 Bone metastases of solid tumors
– breast and prostate carcinoma; other solid tumors
 Osteolytic lesions of multiple myeloma

History of Bisphosphonate
Development
 Mid-19th Century German chemists
– Anti-corrosive in pipelines
 20th Century - Clinical applications
– Tc99 Bone scans
– Toothpaste
 Anti-tartar, anti-plaque effects
– Osteopathies
 Anti-resorptive effect

Basic Chemical Composition
 Pyrophosphate compound
 Substitution of Carbon for
Oxygen
– Resistance to hydrolysis
– Bone matrix accumulation
– Extremely long half-life
 Nitrogen-containing side chain
– Increases potency, toxicity
– Direct link to BRONJ
cases

Normal Osteoclastic Function

Biologic Action of
Bisphosphonates
 Osteoclastic toxicity
– Apoptosis
– Inhibited release of bone
induction proteins
 BMP, ILG1, ILG2
– Reduced bone turnover,
resorption
– Reduced serum calcium*
– Hypermineralization*
 “sclerotic” changes in
lamina dura of alveolar
bone
* = goal of medicinal use

Medical Indications for IV BPs
 Bone metastasis,
hypercalcemia
– Mediated osteoclastic
resorption
 Multiple myeloma, breast
CA, prostate CA
 Paracrine-like effect
– PTH-like peptide
osteoclastic resorption
 Small cell carcinoma,
oropharyngeal cancers
 Endocrine-like effect

Vitamen D diffenecy in adolecent
Review article
International Jounal of Pediatrics , 2014
Soliman ,Kassem et al

Medical Indications for Oral BPs
 Paget’s Disease of bone
– Accelerated bone turnover
 Reduced compressive
strength, increased vascularity
 Bone pain
 Elevated AP levels
 Osteoporosis
– Effects of estrogen loss:
 Decreased bone
turnover/renewal
– Adipocyte differentiation
> osteoblastic
differentiation
– increased fibrofatty
marrow
– Progressively porotic
bone
– DEXA scan for BMD values ismohammed@phcc.gov.qa

Pharmacokinetics
 Oral BP’s
– Absorbed in small intestine
 Less if taken with meal
– 1-10% available to bone
 Circulating half-life: 0.5-2 hrs
– Rapid uptake into bone matrix
– 30-70% of IV/oral dose
accumulates in bone
– Remainder excreted in urine
 Repeated doses accumulate in
bone
– Removed only by osteoclast-
mediated resorption
– “Biologic Catch ”

Etidronate (Didronel)
 Available in both oral and IV
preparations
 Oral: FDA approved for Paget’s
disease
– Dose: 5 mg/kg per day
 IV: approved for use in
hypercalcemia of malignancy
– Dose: 7.5 mg/kg per day
for 3 days
 Risk of osteomalacia w/
prolonged therapy
– do not treat >2 yrs
 No documented cases of
BRONJ

Pamidronate (Aredia)
 Available only as IV preparation
b/c of poor GI absorption and
high freq of GI symptoms
 Approved for tx of
hypercalcemia of malignancy
– one-time dose of 60-90 mg
 Also used for Paget’s disease
 Also used for osteoporosis pt’s
who are unable to tolerate
other bisphosphonates

Zolendronate (Zometa)
 Only available in IV preparation
 Approved for tx of hypercalcemia of
malignancy
 4mg IV over no less than 15 mins

Alendronate (Fosamax)
 Available as oral preparation
 Osteoporosis
– Treatment dose: 10
mg/day or 70 mg weekly
– Prevention dose : 5 mg/day
or 25 mg weekly
 Less inhibition of bone
mineralization
 More suitable for long-term
administration

Risedronate (Actonel)
 Also available as oral
preparation
 Approved for tx of
osteoporosis
 5 mg daily and 35 mg
weekly
– Dose for prevention of
osteoporosis is same as
for treatment

Ibandronate (Boniva)
 Most recently approved for tx
and prevention of osteoporosis
 2.5mg daily or 150 mg
monthly

Bisphosphonate Side Effects
Upset stomach
Inflammation/erosions of esophagus
Fever/flu-like symptoms
Slight increased risk for electrolyte disturbance
Uveitis
Musculoskeletal joint pain
And of course…………………

BRONJ
 Exposed, devitalized bone
in maxillofacial region
 Prior history or current use
of BP
 Vague pain, discomfort
 Spontaneous occurrence,
or…
 2° surgery or trauma to oral
soft tissue/bone

BRONJ: Time line
 Rare reports prior to 2001
 2003: Marx reported 36 patients
 2004: Ruggiero et al reported 63 pts
 (from 2001-2003)
 2005: Migliorati reported 5 cases
 2005: Estilo et al reported 13 cases
 Sept. 2004: Novartis
 (manufacturer of Aredia & Zometa)
 altered labeling to include cautionary language concerning
osteonecrosis of the jaws
 2005: FDA issued warning for entire drug class (including oral
bisphosphonates)

Phossy-Jaw: A Historical Entity
 Lorinser, 1845: first reported cases
 Industrial laborers working w/ white phosphorus powder
– Matchmaking, fireworks factories
– Missile factories
 Clinical presentation
– Non-healing mucosal
– wound following extraction
– Pain
– Fetid odor
– Suppuration
– Necrosis w/ bony sequestra
– Extra-oral fistulae ismohammed@phcc.gov.qa

Similar Clinical Entities
 Closely resembles
Osteopetrosis
– Loss of osteoclastic
function
– Hypermineralization
– Fractures, nonunions,
open oral wounds
– Endpoint: bone necrosis,
+/- infection

NOT to be confused with these other entities:
– Osteoradionecrosis (ORN):
 avascular bone necrosis 2° radiation
– Osteomyelitis:
 thrombosis of small blood vessels leading
to infection within bone marrow
– Steroid-induced osteonecrosis:
 more common in long bones
 exposed bone very rare

Estimated Incidence of BRONJ 2° IV
BPs
 Limited to retrospective studies with
limited sample sizes
 Marx:
– Zometa: exposed bone within 6-12
months
– Aredia: 10-16 months
 Estimates of cumulative incidence of
BRONJ range from 0.8% to 12%
– Marx: 5-15%
 Including Subclinical osteonecrosis
 Incidence will rise:
– Increased recognition
– Increased duration of exposure
– Increased followup

Estimated Incidence of BRONJ
2° Oral BPs
 >190 million oral BP prescriptions dispensed
worldwide
– Much lower risk for BRONJ vs IV administration
 Marx:
– BRONJ development after 3 years of Alendronate usage
 Merck study:
– incidence with Alendronate usage = 0.7/100,000
person/years of exposure
 Estimated incidence of BRONJ w/ weekly
administration of alendronate:
 0.01% to 0.04%
 After extractions, increased to 0.09% to 0.34%

low numbers, so…what’s all the hoopla for?
 Physicians prescribing these meds
– Endocrinologists, Oncologists, GPs, OB-Gyns,etc
– Not well informed of adverse oral effects
 Dentists diagnosing and managing the problem
– Lack of communication between Medicine and Dentistry
– likelihood of many cases unreported
– We are the “experts”…time to bridge the gap
 Effects of oral BPs lagging behind IV BPs
– Another few years for BRONJ to reveal itself among the oral BP
population

Why Only in the Jaws?
 Dixon et al 1997
– Alveolar crest has high remodeling rate
 10x tibia
 5x mandible at level of IA canal
 3.5x mandible at inferior border
 Greater uptake of Tc 99m in bone scans
– Occlusal forces
 Compression at root apex and furcations
 Tension on lamina dura and periodontal ligament
 Remodeling of lamina dura in response
 Reduced remodeling with BP uptake  hypermineralization
– Sclerotic appearance of Lamina dura
– Widening of periodontal ligament space

BRONJ Case Definition
 AAOMS Position Paper (updated September
2014):
– Patients considered to have BRONJ if all 3
characteristics met:
 Current or previous treatment with a bisphosphonate
 Exposed, necrotic bone in maxillofacial region
persisting > 8 weeks
 No history of radiation therapy to jaws

Risk Factors for Development of
BRONJ
 Drug-related factors
– Potency of BP
 Zoledronate > pamidronate > oral BPs
– Duration of therapy
 Local factors
– Dentoalveolar surgery
 Extractions, implants, periapical surgery, periodontal surgery w/
osseous injury
 7-fold risk for BRONJ with IV BPs
 5 to 21-fold risk in some studies
– Local anatomy
 lingual tori, mylohyoid ridge, palatal tori
 Mandible > maxilla (2:1)
– Concomitant oral disease
 7-fold risk for BRONJ with IV BPs

Risk factors (continued)
 Demographic/systemic factors
 Age: 9% increased risk for every passing decade
Multiple myeloma patients treated w/ IV BPs
 Race: Caucasian
 Cancer diagnosis
 multiple myeloma > breast cancer > other cancers
 Osteopenia/osteoporosis diagnosis concurrent w/ cancer diagnosis
 Additional risk factors:
 Corticosteroid therapy
 Diabetes
 Smoking
 Poor oral hygiene
 Chemotherapeutic drugs

BRONJ: Clinical Presentation
 Exposed alveolar bone
– Open mucosal wound
– Necrotic bone
– Spontaneous or
Traumatic
 Extractions,
periodontal surgery,
apicoectomy,
implant placement
 Infection
– Purulence, bone pain
– Orocutaneous fistula

BRONJ: Clinical Presentation
 Subclinical Form
– asymptomatic
– radiographic signs
 Sclerosis of lamina
dura
 Widening of PDL
space

Clinical Presentation (cont)…
 Soft tissue abrasions
– Tissues rubbing against
bone
 AND………

More frequently
 Lesions more
extensive
All stages
 II, III more
common
Lower success with
Tx
Patients generally
sicker
BRONJ: IV BPs

Pathologic Fracture

Staging of BRONJ
 Proposed by AAOMS:
– Patients at risk (Subclinical)
 No apparent exposed/necrotic bone in pts treated w/ IV or oral
BPs
– Patients with BRONJ
 Stage 1: Exposed/necrotic bone, asymptomatic, no infection
 Stage 2: Exposed/necrotic bone, pain, clinical evidence of
infection
 Stage 3: Exposed/necrotic bone, pain, infection, one or
more of the following:
– Pathologic fracture, extra-oral fistula, osteolysis extending
to inferior border

Stage 0 Lesions
 Spontaneous onset
numbness and pain
 No exposed bone
 No prior dental antecedent
 Positive image findings:
– Sclerosis
– Positive bone scan

Subclinical Risk Assessment
Early signs of BP toxicity:
– Radiographs
 Panoramic, PA films
– Sclerosis of alveolus, lamina dura
– Widening of PDL space
– Clinical exam
 Tooth mobility
– Unrelated to alveolar bone loss
 Deep bone pain with no apparent etiology

Risk Assessment: Bone Turnover Markers
 Bone Turnover Markers
– Most assess bone formation
 AP, osteocalcin
 Marx: Serum CTX marker
– Bone resorption
– Oral BP risk
– Type I collagen telopeptide
assay
 ELISA/RIA – Quest
Diagnostics
– Cleaved at carboxyl end by
osteoclast in bone resorption
 NTX – marker cleaved at
amine end
– Requires 1 mL whole blood –
fasting

Serum CTX Peptide
 Low values = high risk
– Little osteoclastic function
 Marx, et al 2007 (JOMS)
– 17 pts on oral BPs > 5 years
– CTX before/after drug holiday
(6mos)
– Before drug holiday:
 CTX range 30-102 pg/mL
– After drug holiday:
 CTX range 162-343 pg/mL
over 6 months
 Improved mucosal healing
– Drug holiday allows for
osteoclast recovery
– 4-6 months: reasonable, safe,
and minimizes risk of BRONJ

Stage I Lesions

Stage II Lesions

Stage III Lesions

Treatment Goals
 Preserve Quality of Life
– Pain Control
– Treat 2° infection
– Prevent extension

What this means for you as a
practitioner
 Routine dental care a MUST for BRONJ pts and Non-
BRONJ pts taking BPs
 dental prophylaxis
 nonoperative periodontal care
 restorative procedures
 conventional fixed and removable prosthodontics
 Invasive procedures on case-by-case basis
 Elective oral surgery
 apical surgery
 periodontal bone recontouring
 implants
 orthodontic tooth movement

Treatment Strategies
 Patients about to initiate IV bisphosphonate
tx
– Objective: minimize risk of developing BRONJ
– Dental prophylaxis, caries control, conservative restorative
dentistry
– Adjustment of denture flanges to minimize mucosal trauma
– Extraction of nonrestorable teeth
– Completion of elective dentoalveolar surgery
– If systemic conditions permit:
 Delay Bisphosphonate therapy until dental health optimized
 14-21 days after extractions

 Asymptomatic patients receiving IV BPs
– Maintenance of good oral hygiene, dental care
– Avoid invasive procedures
 Nonrestorable teeth:
– Remove crowns
– Endodontic treatment of remaining roots
 Avoid placement of implants

 Asymptomatic patients receiving oral BPs
– Less than 3 years with no clinical risk factors:
 No alteration or delay in elective surgery
 Implants permitted
– Discuss risks
– Regular recall schedule
 Discuss with PCP re: alternate dosing, drug
holidays !!!, BP alternatives

 Asymptomatic patients receiving oral BPs
(continued)
– Less than 3 years, concomitant steroid use
 Contact PCP re: drug holiday for at least 3 months prior to
surgery
 Restarted after osseous healing complete (3 months)
– More than 3 years, with/without concomitant steroid use
 Contact PCP re: drug holiday for 3 months prior to oral
surgery
 Restarted after osseous healing complete
– CTX???

Conservative extraction??
ikassem@dr.com

 Patients with Established Diagnosis of
BRONJ
– Objectives: eliminate pain, control infection, minimize
progression/occurrence of necrosis
– Marx:
 debridement may worsen condition
– Removal of bone serving as soft tissue irritant, loose
bony sequestra
 Without exposure of uninvolved bone
– Extraction of teeth within exposed, necrotic bone
– Avoid elective dentoalveolar surgery

 Stage III disease
– Pathologic fractures, refractory
cases
 Preservation of function
– Airway, speech
compromise with large
mandible resections
 Segmental resections,
titanium plate
reconstruction, external
fixation.
– All infections must be
cleared first
 Delay
reconstruction up to
3 months
– Avoid bone grafting

Just write islam kassem on
google & download the lectures

An ounce of prevention is worth
a pound of cure.
Thank you

MRONJ

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to MRONJ

Similar to MRONJ (20)

More from islam kassem

More from islam kassem (20)

Recently uploaded

Recently uploaded (20)

MRONJ